2024-10-15 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and manufactures medicines in various therapeutic areas, including diabetes, oncology, and neurology.

**Performance Summary:**

**1. Performance Comparison:**

* **Cumulative Return:** LLY - 899.89%, VOO (S&P 500) - 135.82%.
* **Performance Gap:** LLY has outperformed the S&P 500 significantly, with a substantial difference in cumulative returns. 
* **Relative Performance:** The current performance gap puts LLY at the 94.74% percentile of its historical range.

**2. Recent Price Action:**

* **Closing Price:** $932.06
* **5-Day Moving Average:** $914.5
* **20-Day Moving Average:** $906.22
* **60-Day Moving Average:** $894.98
* **Interpretation:** The stock price is currently above all three moving averages, indicating an upward trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 54.89. The RSI is in the neutral zone, suggesting neither overbought nor oversold conditions.
* **PPO (Percentage Price Oscillator):** 0.31. A positive value indicates bullish momentum.
* **Delta_Previous_Relative_Divergence:** -0.2. This indicates a slight downward trend in the relative performance over the past 20 days.
* **Expected Return:** 24.91%. This suggests a potential for significant outperformance compared to the S&P 500 over the next five years.

**4. Recent Earnings and Outlook:**

* **Recent Earnings:**
    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-08-08 | 3.29 | $11.30B |
    | 2024-04-30 | 2.49 | $8.77B |
    | 2023-11-02 | -0.06 | $9.50B |
    | 2023-08-08 | 1.96 | $8.31B |
    | 2024-08-08 | 1.96 | $8.31B |
* **Analysis:** Eli Lilly has shown consistent revenue growth over the past quarters, exceeding analyst expectations. 
* **Latest Earnings:** The latest earnings report on August 8th, 2024 showed impressive results with EPS exceeding expectations. 

**5. News and Recent Developments:**

* **Recent Market Outlook:**  Eli Lilly is currently enjoying a positive market outlook, driven by strong drug pipelines and growth in key therapeutic areas.
* **Analyst Opinions:**  Most analysts maintain a "Buy" rating on LLY, citing strong fundamentals and future growth potential.
* **Performance Highlights:** Eli Lilly has consistently delivered impressive financial performance, evidenced by strong revenue growth, increasing market share, and a robust drug pipeline.

**6. Overall Analysis:**

Eli Lilly and Co (LLY) presents a compelling investment opportunity with a strong track record of outperformance.  The company enjoys a positive market outlook, robust financial performance, and a promising drug pipeline. The current technical indicators suggest a positive short-term trend, while the long-term outlook remains favorable. 

**Note:** This analysis is based on publicly available information and should not be considered financial advice. Always consult with a qualified financial professional before making any investment decisions. 
